Precision Medicine Patents

Precision medicine patents span companion diagnostics; liquid biopsy; pharmacogenomics; multi-cancer early detection; and polygenic risk scoring — with major activity from genomics companies; clinical laboratory companies; and pharmaceutical-diagnostics partnerships: MAJOR PRECISION MEDICINE PATENT HOLDERS: FOUNDATION MEDICINE (ROCHE): 500+; specific comprehensive genomic profiling (CGP) (specific FoundationOne CDx: specific specific hybrid capture-based targeted NGS panel for specific specific 324 cancer gene hotspot + specific specific exon region from specific specific FFPE tissue; specific specific bioinformatics pipeline for specific specific TMB (tumor mutational burden: specific specific mutations/Mb threshold ≥10 mut/Mb for specific specific immunotherapy biomarker); specific specific MSI-H (microsatellite instability: specific specific repeat length instability at specific specific 95 loci for specific specific MMR-deficient tumor identification); specific specific FDA-approved CDx companion diagnostic for specific specific pembrolizumab (Keytruda) pan-tumor TMB-H + MSI-H); GUARDANT HEALTH: 500+; specific liquid biopsy ctDNA (specific specific Guardant360 CDx: specific specific cell-free circulating tumor DNA cfDNA extraction from specific specific plasma + specific specific hybrid-capture panel amplification for specific specific 74 gene SNV+INDEL+CNV+fusion + specific specific epigenomic analysis from specific specific blood draw without specific specific tissue biopsy; specific specific error suppression: specific specific UMI unique molecular identifier duplex sequencing for specific specific 0.1% VAF sensitivity); GRAIL (ILLUMINA DIVESTED 2024): 500+; specific Galleri (specific specific multi-cancer early detection MCED: specific specific cell-free DNA methylation pattern from specific specific whole-genome bisulfite sequencing for specific specific tissue-of-origin inference: specific specific cancer signal detection across specific specific 50+ cancer types from specific specific single blood draw using specific specific ML classifier with specific specific measured PPV + specific specific measured cancer signal origin accuracy at specific specific specific CCGA/PATHFINDER clinical study); MYRIAD GENETICS: 1,000+; specific BRCA1/2 hereditary cancer testing (specific specific BRACAnalysis CDx: specific specific FDA-approved CDx for specific specific olaparib/rucaparib PARP inhibitor in specific specific BRCA1/2-positive breast+ovarian cancer); GENOMIC HEALTH (EXACT SCIENCES): 1,000+; specific Oncotype DX (specific specific 21-gene RT-PCR recurrence score from specific specific FFPE for specific specific early-stage ER+ breast cancer adjuvant chemotherapy decision); VERACYTE: 500+; specific Afirma thyroid (specific specific 142-gene expression classifier GEC for specific specific thyroid nodule malignancy risk stratification vs. fine needle aspiration).

Liquid biopsy error suppression; multi-cancer early detection from epigenomic signatures; and pharmacogenomics for drug dosing optimization represent three technically differentiated and commercially high-value patent areas in precision medicine: LIQUID BIOPSY ERROR SUPPRESSION PATENTS: GUARDANT HEALTH; GRAIL; ROCHE; QIAGEN; SYSMEX: specific unique molecular identifier UMI error suppression (specific specific UMI-based duplex sequencing: specific specific double-strand barcode ligation to specific specific both ends of specific specific cfDNA fragment before specific specific library amplification for specific specific consensus calling: specific specific both strands must call same variant for specific specific true somatic variant vs. specific specific artifact at specific specific <0.01% VAF detection limit; specific specific error rate reduction from specific specific 10^-4 polymerase error to specific specific 10^-7 duplex consensus); specific in silico error suppression (specific specific machine learning artifact filter trained on specific specific healthy donor cfDNA error signature for specific specific sequencing artifact + specific specific clonal hematopoiesis CHIP contamination removal from specific specific somatic variant calling); specific digital PCR for cfDNA quantification (specific specific ddPCR: specific specific emulsion partitioning of specific specific cfDNA template across specific specific 20,000 droplets for specific specific specific Poisson statistics-based absolute copy number from specific specific single-molecule counting without specific specific reference standard); MULTI-CANCER EARLY DETECTION (MCED) PATENTS: GRAIL; EXACT SCIENCES; VOLITION; NUCLEIX: specific cfDNA methylation MCED (specific specific whole-genome bisulfite sequencing WGBS from specific specific cell-free plasma DNA for specific specific CpG methylation pattern: specific specific methylation deconvolution: specific specific tissue-of-origin reference atlas + specific specific ML classifier for specific specific cancer-specific methylation signature detection with specific specific measured sensitivity at specific specific 99% specificity across specific specific 50+ cancer types); specific cfDNA fragmentomics (specific specific cfDNA fragment size distribution + specific specific end motif + specific specific preferred end site mapping for specific specific nucleosome positioning inference from specific specific GRAIL cancer cohort for specific specific cancer signal without specific specific methylation sequencing); PHARMACOGENOMICS PATENTS: MYRIAD GENETICS; CLINICAL PHARMACOGENOMICS (CPG) IMPLEMENTATION CONSORTIUM; GENOMIND: specific CYP2D6 pharmacogenomics (specific specific CYP2D6 genotyping by specific specific NGS + specific specific allele-star classification: specific specific CYP2D6*1/*3/*4/*5/*6/*10/*17 for specific specific predicted metabolizer phenotype: specific specific poor + specific specific intermediate + specific specific normal + specific specific ultra-rapid for specific specific codeine+tamoxifen+antidepressant dose optimization; specific specific CPIC guideline-consistent dosing recommendation algorithm from specific specific specific diplotype → specific specific specific phenotype → specific specific specific dose recommendation).

Polygenic risk scores; tumor neoantigen vaccines; and proteomics-based diagnostics represent three emerging IP frontiers in precision medicine — each at the intersection of genomics; AI; and personalized therapeutics: POLYGENIC RISK SCORE (PRS) PATENTS: 23ANDME; REGENERON GENETICS CENTER; GENOMIC PREDICTION; MYRIAD GENETICS; CAMBRIDGE AI GENETICS (BROAD INSTITUTE SPINOUT): specific PRS algorithm (specific specific genome-wide association study GWAS summary statistics from specific specific specific large biobank — specific specific UK Biobank 500K + specific specific Million Veteran Program — + specific specific LD reference panel for specific specific LDpred2 or specific specific PRSice2 or specific specific AnnoPred Bayesian posterior effect size shrinkage for specific specific individual polygenic risk score computation from specific specific specific directly genotyped or specific specific specific imputed array SNP genotype at specific specific specific 1M+ SNPs); specific clinical PRS interpretation (specific specific population-adjusted percentile report: specific specific ancestry-specific PRS quintile calibration + specific specific absolute risk conversion via specific specific competing risk model for specific specific cardiovascular+breast cancer+type 2 diabetes clinical communication); TUMOR NEOANTIGEN VACCINE PATENTS: MODERNA; BIONTECH; NEON THERAPEUTICS (BMS): specific personalized mRNA neoantigen vaccine (specific specific WES+RNA-seq of specific specific tumor biopsy + specific specific AI-driven neoantigen prediction: specific specific HLA typing by specific specific HLA-HD from specific specific specific sequencing data → specific specific specific pMHC binding affinity NetMHCpan4.1 prediction → specific specific neoantigen ranking by specific specific specific binding affinity + specific specific clonal fraction + specific specific expression level for specific specific specific mRNA vaccine manufacturing within specific specific specific ~6 week turnaround from specific specific specific biopsy to specific specific specific injection; Moderna mRNA-4157 + pembrolizumab clinical data MRNA-4157-P201 Phase 2 melanoma 44% RFS improvement 2023); PROTEOMICS-BASED DIAGNOSTICS PATENTS: SOMALOGIC (STANDARD BIOTOOLS); OLINK; NAUTILUS BIOTECHNOLOGY; ALAMAR BIOSCIENCES: specific aptamer-based proteomics (specific specific SOMAscan assay: specific specific single-stranded DNA aptamer SOMamer with specific specific slow off-rate: specific specific 3D chemical modification for specific specific protein binding + specific specific photoaptamer crosslinking for specific specific specific 7,000+ protein simultaneous measurement from specific specific specific 55 μL serum; specific specific protein biomarker panel → specific specific disease risk ML model); specific proximity extension assay PEA (specific specific Olink: specific specific two antibody-DNA conjugates for specific specific target protein proximity ligation → specific specific PCR amplification for specific specific 96-3072 protein simultaneous measurement from specific specific specific 1 μL sample).

Precision medicine startups operate in a sector where clinical validation; FDA regulatory approval; payor coverage; and physician adoption create barriers to competition that extend well beyond intellectual property alone — and where the right IP strategy integrates patent; trade secret; and regulatory exclusivity tools: PRECISION MEDICINE STARTUP IP STRATEGY: UNDERSTAND THE PRECISION MEDICINE IP LANDSCAPE: MYRIAD GENETICS WAKE-UP CALL: Myriad Genetics v. Association for Molecular Pathology (S.Ct. 2013) = naturally occurring DNA sequences NOT patentable; genomic mutations = not patentable; BUT: specific cDNA; specific specific isolated oligo probes; specific specific assay method using specific specific primers + specific specific probes with specific specific measured clinical performance = patentable; MAYO-ALICE TWIN THREAT FOR BIOMARKER CLAIMS: biomarker correlation claim = law of nature risk (Mayo); pure data analysis = abstract idea risk (Alice); SURVIVAL: claim specific assay method steps + specific hardware + specific measured clinical outcome on specific specific validated cohort (specific specific sensitivity+specificity+PPV+NPV on specific specific specific intended use population); FDA CDX REGULATORY PATHWAY = POWERFUL IP SUBSTITUTE: specific FDA-approved companion diagnostic (CDx): specific specific PMA or specific specific 510(k) clearance for specific specific drug-diagnostic co-approval creates specific specific regulatory moat: competitor must obtain own FDA approval; FDA approval signals clinical validity + creates prescribing signal; PARS (PRIOR AUTHORIZATION) AS COMMERCIAL BARRIER: payor coverage decisions (specific specific CMS LCD NCD local/national coverage determination) take specific 2-5 years = significant commercial barrier beyond IP; WHEN TO PATENT IN PRECISION MEDICINE: SPECIFIC NOVEL ASSAY METHOD: specific novel cfDNA error suppression method with specific measured VAF sensitivity + specific specific specificity on specific specific specific population at specific specific specific clinical indication (cancer type; stage); SPECIFIC NOVEL BIOMARKER COMBINATION: specific novel biomarker panel (specific specific specific N biomarkers from specific specific specific sample type) with specific specific measured clinical performance (specific specific AUROC + specific specific PPV + specific specific NPV) in specific specific specific validated clinical cohort for specific specific specific clinical indication — method of diagnosis claim; SPECIFIC NOVEL PRS ALGORITHM: specific novel PRS algorithm with specific measured discrimination (C-statistic; NRI; IDI) vs. clinical risk factor model baseline on specific specific specific biobank cohort; SPECIFIC NOVEL NEOANTIGEN PREDICTION: specific novel neoantigen ranking algorithm with specific measured immunogenicity (T-cell response rate) in specific specific clinical trial vs. standard neoantigen selection; TRADE SECRETS: specific bioinformatics variant calling pipeline calibrated to specific clinical-grade NGS instrument; specific specific ML biomarker model weights trained on specific specific proprietary clinical cohort; specific specific CDx bioinformatics analytical validation protocol; KEY FTO: Foundation Medicine CGP TMB/MSI-H CDx FoundationOne; Guardant Health ctDNA UMI duplex liquid biopsy; GRAIL cfDNA methylation MCED Galleri; Myriad BRCA1/2 BRACAnalysis CDx; Exact Sciences Oncotype DX 21-gene RT-PCR; Veracyte Afirma thyroid GEC; Moderna mRNA neoantigen vaccine personalized; SomaLogic SOMAscan aptamer proteomics.